319 related articles for article (PubMed ID: 31652991)
1. The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin.
Traini C; Vannucchi MG
Toxins (Basel); 2019 Oct; 11(11):. PubMed ID: 31652991
[TBL] [Abstract][Full Text] [Related]
2. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
Chen SF; Chang CH; Kuo HC
Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
Lin YH; Chiang BJ; Liao CH
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085522
[TBL] [Abstract][Full Text] [Related]
4. Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies.
Traini C; Del Popolo G; Faussone-Pellegrini MS; Guasti D; Catarinicchia S; Vannucchi MG
J Cell Mol Med; 2019 Jun; 23(6):4076-4087. PubMed ID: 30945429
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
Conte A; Giannantoni A; Proietti S; Giovannozzi S; Fabbrini G; Rossi A; Porena M; Berardelli A
Eur J Neurol; 2012 May; 19(5):725-32. PubMed ID: 22212295
[TBL] [Abstract][Full Text] [Related]
6. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F; Nitti V
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
[TBL] [Abstract][Full Text] [Related]
7. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.
Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P
J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019
[TBL] [Abstract][Full Text] [Related]
8. Effect of botulinum neurotoxin on the urinary bladder: novel insights on mechanism of action.
Vianello A; Proietti S; Giannantoni A
Minerva Urol Nefrol; 2010 Sep; 62(3):259-71. PubMed ID: 20940695
[TBL] [Abstract][Full Text] [Related]
9. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Nambiar A; Lucas M
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
[TBL] [Abstract][Full Text] [Related]
10. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
Linsenmeyer TA
J Spinal Cord Med; 2013 Sep; 36(5):402-19. PubMed ID: 23941788
[TBL] [Abstract][Full Text] [Related]
11. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.
Apostolidis A; Popat R; Yiangou Y; Cockayne D; Ford AP; Davis JB; Dasgupta P; Fowler CJ; Anand P
J Urol; 2005 Sep; 174(3):977-82; discussion 982-3. PubMed ID: 16094018
[TBL] [Abstract][Full Text] [Related]
12. BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study.
Maignel J; Martin V; Assaly R; Vogt ML; Retailleau K; Hornby F; Laugerotte A; Lezmi S; Denys P; Krupp J; Joussain C
Toxins (Basel); 2022 Jan; 14(2):. PubMed ID: 35202105
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of onobotulinumtoxinA as a therapeutic option for pediatric neurogenic detrusor overactivity.
Peard LM; Pope JC; Dmochowski R
Expert Rev Neurother; 2023; 23(9):763-774. PubMed ID: 37556757
[TBL] [Abstract][Full Text] [Related]
14. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
Alloussi SH; Lang Ch; Eichel R; Al-Kaabneh A; Seibold J; Schwentner C; Alloussi S
World J Urol; 2012 Jun; 30(3):367-73. PubMed ID: 21842216
[TBL] [Abstract][Full Text] [Related]
15. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
[TBL] [Abstract][Full Text] [Related]
16. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
[TBL] [Abstract][Full Text] [Related]
17. Impact of the suspension of neurogenic detrusor overactivity treatment with botulinum toxin due to the COVID-19 pandemic.
Freitas Ferreira E; Silva R; Ferreira A; Paz Carvalho M; Vale P; Faria F
Urologia; 2023 May; 90(2):387-394. PubMed ID: 35880710
[TBL] [Abstract][Full Text] [Related]
18. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.
Apostolidis A; Rahnama'i MS; Fry C; Dmochowski R; Sahai A
Neurourol Urodyn; 2016 Feb; 35(2):293-8. PubMed ID: 26872570
[TBL] [Abstract][Full Text] [Related]
19. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
